Comparative Effects of Diet-Induced Lipid Lowering Versus Lipid Lowering Along with Apo A-I Milano Gene Therapy on Regression of Atherosclerosis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 21, Issue 3, 2016, Pages 320-328

  Wang, Lai ^a   Tian, Fang ^a   Arias, Ana ^a   Yang, Mingjie ^a   Sharifi, Behrooz G ^a   Shah, Prediman K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

adeno associated virus; apolipoprotein A I Milano; atherosclerosis; gene therapy

Indexed keywords

APOLIPOPROTEIN A1 MILANO; CHOLESTEROL; GENE THERAPY AGENT; UNCLASSIFIED DRUG; APOLIPOPROTEIN A-I MILANO; APOLIPOPROTEIN A1; APOLIPOPROTEIN E;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIET THERAPY; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LOW CHOLESTEROL DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; POLARIZATION; PRIORITY JOURNAL; REMISSION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; AORTIC DISEASES; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD; COMPARATIVE STUDY; DEFICIENCY; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; LOW FAT DIET; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHENOTYPE; PROCEDURES;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; COMBINED MODALITY THERAPY; DEPENDOVIRUS; DIET, FAT-RESTRICTED; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; GENETIC VECTORS; MACROPHAGES; MALE; MICE, KNOCKOUT; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; REMISSION INDUCTION;

EID: 84963685530     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248415610216     Document Type: Article

References (17)

1. Franceschini G, Sirtori CR, Capurso A II, Weisgraber KH, Mahley RW,. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980; 66 (5): 892-900.
2. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR,. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest. 1980; 66 (5): 901-907.
3. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 2001; 103 (15): 1949-1954.
4. Gomaraschi M, Baldassarre D, Amato M, et al. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. Circulation. 2007; 116 (19): 2165-2172.
5. Wang L, Sharifi BG, Pan T, Song L, Yukht A, Shah PK,. Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol. 2006; 48 (7): 1459-1468.
6. Tian F, Wang L, Arias A, Yang M, Sharifi BG, Shah PK,. Comparative antiatherogenic effects of intravenous AAV8- and AAV2-mediated ApoA-IMilano gene transfer in hypercholesterolemic mice. J Cardiovasc Pharmacol Ther. 2015; 20 (1): 66-75.
7. Bielicki JK, Oda MN,. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 2002; 41 (6): 2089-2096.
8. Feng Y, Van Craeyveld E, Jacobs F, Lievens J, Snoeys J, De Geest B,. Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. J Mol Med. 2009; 87 (3): 287-297.
9. Lebherz C, Sanmiguel J, Wilson JM, Rader DJ,. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol. 2007; 6: 15.
10. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994; 90 (4): 1935-1941.
11. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998; 97 (8): 780-785.
12. Kaul S, Coin B, Hedayiti A, et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol. 2004; 44 (6): 1311-1319.
13. Ibanez B, Vilahur G, Cimmino G, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol. 2008; 51 (11): 1104-1109.
14. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol. 2008; 51 (11): 1098-1103.
15. Reardon CA, Blachowicz L, Lukens J, Nissenbaum M, Getz GS,. Genetic background selectively influences innominate artery atherosclerosis: immune system deficiency as a probe. Arterioscler Thromb Vasc Biol. 2003; 23 (8): 1449-1454.
16. Shah PK,. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr Opin Cardiol. 2010; 25 (6): 603-608.
17. Sharifi BG, Wu K, Wang L, Ong JM, Zhou X, Shah PK,. AAV serotype-dependent apolipoprotein A-I Milano gene expression. Atherosclerosis. 2005; 181 (2): 261-269.